Gene Expression of B16F10 Induced by Treatment with 5-aza-2'-deoxycytidine / 대한이비인후과학회지

BACKGROUND AND OBJECTIVES: The goal of tumor vaccine is to activate immune system specifically against proteins expressed by a tumor, and many types of vaccines such as gene modified vaccines have been developed to increase immunogenicity of vaccine. We studied to determine whether or not 5-aza-2'-deoxycytidine (ADC) can increase the immunogenicity of B16F10 melanoma cell. MATERIALS AND METHOD: B16F10 cell was treated with ADC for the induction of DNA demethylation. An ADC treated B16F10 melanoma cell was analyzed first using the reverse transcriptase-polymerase chain reaction (RT-PCR) technique to evaluate the gene expression of tumor antigen (MAGE-2, MAGE-5) and immunity-enhancing cytokines (GM-CSF, IL-12), and then by flow cytometry to evaluate the expression of MHC and B7 that are responsible for antigen expression and T cell activation on B16F10 cell surface. In order to evaluate vaccination effect of ADC-treated B16F10 vaccine, each mouse group were injected with PBS, ADC, B16F10 vaccine or B16F10-ADC vaccine and they were also challenged with live B16F10 cell 7 days after vaccination. On the 20th day after live B16F10 cell challenge, the tumor mass size and the mouse survival period were determined. RESULTS: ADC treatment for B16F10 melanoma cell increased expression of MHC and B7. ADC treatment also increased gene expression of MAGE-2, MAGE-5, GM-CSF and IL-12. The growth of tumor mass was decreased and the mouse survival period was elongated in B16F10-ADC vaccine immunized group. CONCLUSION: ADC treatment may increase immunogenicity of B16F10 cell, and B16F10-ADC vaccine immunization can induce anti-cancer immunity in vivo.

Cytogenetic Studies of High Dose EGF Treated KUMA3 Cell Clone / 대한이비인후과학회지

BACKGROUND AND OBJECTIVES: Epidermal growth factor (EGF), directly stimulates epidermal growth and differentiation. The combination of EGFR activation and genetic alternations may lead to neoplasia and metaplasia. To study the change of chromosomal number and the aberrations of chromosomal structure of KUMA3 cell line treated with high dose EGF. MATERIALS AND METHODS: The high dose EGF treated cell clones were obtained from KUMA3 cell line which was established from squamous cell carcinoma of the lower lip by culturing cells in medium containing high dose EGF for 6 months. The chromosomal analysis and subculture were performed at subsequent passage of 1 month interval. RESULTS: In high dose EGF treated cell clones, there was no apparent change in chromosomal number, but the ratio of the number of chromosome 7 to mode chromosome number was similar to normal value (0.043). The new chromosomal structural aberrations appeared first from 30 passage of IR-200 cell clone. The chromosomal aberrations were del(1)(q23-->qter) and del(4)t(1:4)(1qter-->1q23: : 4p16-->4qter). CONCLUSION: There was no change in chromosomal number, but the ratio of the number of chromosome 7 to mode chromosome number was similar to normal value (0.043), and the new chromosomal structural aberrations were appeared.

Symptom Relief after Endoscopic Sinus Surgery:A Prospective Analysis / 대한이비인후과학회지

Chronic paranasal sinusitis is one of the most common disease in the field of otolaryngology, and endoscopic sinus surgery(ESS) is efficient and safe operative method of chronic paranasal sinusitis. We employed socalled symptom score to quantify the common sinusitis related symptoms before and after endoscopic sinus surgery which followed up to 6 months. A prospective study of 50 patients all having undergone ESS from June, 1995 to February, 1996 was performed and we analyzed the surgical results using questionaires which focused on six common sinusitis related symptoms-nasal obstruction, rhinorrhea, olfactory disturbance, postnasal drip, headache and sneezing. Postoperative symptom relief was apparent in all six common symptoms(p value<0.001) and the higher sinusitis stage, the more relief of sinusitis related symptoms(p value=0.029). It seems to be helpful to employ a symptom score in predicting and analyzing the surgical results in the treatment of chronic sinusitis.